HTA306 Surrogate Endpoints in German Health Technology Assessment: Post Hoc Analyses of the Phase III PROTECT Study Highlight the Efficacy of Sparsentan in Slowing Down the Loss of Kidney Function in IgAN Patients
Abstract
Authors
Matthias Roll Thomas Hardt Amadeus Gladbach Jürgen Floege